跳到主要內容區塊
  1. 首頁

論文發表

論文發表列表

2025

  1. Chang, T. C., Wang, C. M., Ho, C. H., Chen, Y. C., Liao, C. T., Shieh, J. M., & Chang, W. T. (2025). A prevalence study focusing on hospitalized COPD related pulmonary hypertension. Sci Rep, 15(1), 12426. https://doi.org/10.1038/s41598-025-96629-9
  2. Chang, W. T., Lin, H. W., Liu, C. H., Lin, S. H., & Li, Y. H. (2025). Association between immune checkpoint inhibitors and cardiovascular risks: a nationwide self-controlled case series study. Am J Cancer Res, 15(4), 1820-1828.https://doi.org/10.62347/zuua2691
  3. Chang, W. T., Wu, C. C., Liao, I. C., Lin, Y. W., Chen, Y. C., Ho, C. H., Lee, W. C., Lin, Y. C., Chen, Z. C., Shih, J. Y., Wu, N. C., & Kan, W. C. (2025). Corrigendum to "Dapagliflozin protects against doxorubicin-induced nephrotoxicity associated with nitric oxide pathway-a translational study" [Free Radic. Biol. Medi. 208 (2023) 103-111]. Free Radic Biol Med, 233, 422-423. https://doi.org/10.1016/j.freeradbiomed.2025.04.002
  4. Chen, C. L., Yang, W. S., Yang, H. I., Chen, C. F., Wang, L. Y., Lu, S. N., Kao, J. H., Chen, P. J., & Chen, C. J. (2025). Plasma Adiponectin Levels in Relation to Chronic Hepatitis B Infection Progression to Liver Cancer Milestones: A Prospective Study. Liver Cancer, 14(1), 19-35. https://doi.org/10.1159/000539909
  5. Chen, W. Y., Shih, H. L., Lee, Y. T., Chang, R., Liang, W. M., Hung, Y. M., & Sun, C. K. (2025). Risk of acute myocardial infarction in patients with non-typhoidal Salmonella infection: A nationwide matched population-based cohort study. Public Health, 242, 406-412. https://doi.org/10.1016/j.puhe.2025.03.019
  6. Chen, Y. C., Tsai, P. C., Huang, C. F., Chen, C. Y., Hung, C. H., Chen, C. H., Tai, C. M., Cheng, P. N., Kuo, H. T., Mo, L. R., Lo, C. C., Huang, Y. H., Lin, H. C., Lee, P. L., Bair, M. J., Chang, T. S., Lin, C. Y., Wang, S. J., Hsieh, T. Y., . . . Yu, M. L. (2025). High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C. J Formos Med Assoc. https://doi.org/10.1016/j.jfma.2025.01.026
  7. Chen, Y. Y., Chen, C. S., Huang, J. F., Su, W. H., Li, C. Y., Chen, W. S., Lin, E. S., Chuang, W. L., Yu, M. L., & Wang, S. C. (2025). The obesity-related mutation gene on nonalcoholic fatty liver disease. Hum Genet, 144(1), 1-14. https://doi.org/10.1007/s00439-024-02686-x
  8. Eslam, M., Fan, J. G., Yu, M. L., Wong, V. W., Cua, I. H., Liu, C. J., Tanwandee, T., Gani, R., Seto, W. K., Alam, S., Young, D. Y., Hamid, S., Zheng, M. H., Kawaguchi, T., Chan, W. K., Payawal, D., Tan, S. S., Goh, G. B., Strasser, S. I., . . . George, J. (2025). The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int, 19(2), 261-301. https://doi.org/10.1007/s12072-024-10774-3
  9. Hong, C. S., Wu, N. C., Lin, Y. W., Lin, Y. C., Shih, J. Y., Niu, K. C., Lin, M. T., Chang, C. P., Chen, Z. C., Kan, W. C., & Chang, W. T. (2025). Hyperbaric oxygen therapy attenuated limb ischemia in mice with high-fat diet by restoring Sirtuin 1 and mitochondrial function. Free Radic Biol Med, 230, 263-272. https://doi.org/10.1016/j.freeradbiomed.2025.01.056
  10. Hsu, C. H., Chen, C. F., Yin, C. H., Chen, Y. S., & Chen, J. S. (2025). Antihistamines Improve the Survival of Lung Cancer: A 10-Year Cohort Study of Tertiary Hospital in Taiwan. Oncology, 1-10. https://doi.org/10.1159/000545458
  11. Hua, C. H., Lin, J. C., Wen, Y. W., Kang, C. J., Lin, C. Y., Ku, H. Y., Fan, K. H., Ng, S. H., Lee, S. R., Tsai, Y. T., Chen, W. C., Lee, L. Y., Chien, C. Y., Wang, C. P., Che, T. M., Terng, S. D., Tsai, C. Y., Wang, H. M., Hsieh, C. H., . . . Liao, C. T. (2025). Is postoperative adjuvant therapy necessary for pT3N0 oral cavity squamous cell carcinoma? Oral Oncol, 162, 107198. https://doi.org/10.1016/j.oraloncology.2025.107198
  12. Huang, C. F., Yeh, M. L., Dai, C. Y., Huang, J. F., Chuang, W. L., & Yu, M. L. (2025). Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on "Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan". Clin Mol Hepatol, 31(1), e64-e66. https://doi.org/10.3350/cmh.2024.0638
  13. Huang, R., Jun, D. W., Toyoda, H., Hsu, Y. C., Trinh, H., Nozaki, A., Ishikawa, T., Watanabe, T., Uojima, H., Huang, D. Q., Honda, T., Tanaka, Y., Vutien, P., Marciano, S., Abe, H., Enomoto, M., Atsukawa, M., Takahashi, H., Tsuji, K., . . . Nguyen, M. H. (2025). Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatment. Clin Mol Hepatol. https://doi.org/10.3350/cmh.2024.1070
  14. Jang, T. Y., Zeng, Y. T., Liang, P. C., Wu, C. D., Wei, Y. J., Tsai, P. C., Hsieh, M. Y., Lin, Y. H., Hsieh, M. H., Wang, C. W., Yang, J. F., Yeh, M. L., Huang, C. F., Chuang, W. L., Huang, J. F., Cheng, Y. Y., Dai, C. Y., Chen, P. C., & Yu, M. L. (2025). Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues. Aliment Pharmacol Ther, 61(9), 1458-1466. https://doi.org/10.1111/apt.70019
  15. Jang, T. Y., Zeng, Y. T., Liang, P. C., Wu, C. D., Wei, Y. J., Tsai, P. C., Hsu, P. Y., Hsieh, M. Y., Lin, Y. H., Hsieh, M. H., Wang, C. W., Yang, J. F., Yeh, M. L., Huang, C. F., Chuang, W. L., Huang, J. F., Cheng, Y. Y., Dai, C. Y., Chen, P. C., & Yu, M. L. (2025). Role of Air Pollution in Development of Hepatocellular Carcinoma Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues. Liver Int, 45(4), e16149. https://doi.org/10.1111/liv.16149
  16. Kang, C. J., Wen, Y. W., Lin, C. Y., Ng, S. H., Tsai, Y. T., Ku, H. Y., Lou, P. J., Wang, C. P., Lin, J. C., Hua, C. H., Lee, S. R., Fan, K. H., Chen, W. C., Lee, L. Y., Chien, C. Y., Chen, T. M., Terng, S. D., Tsai, C. Y., Wang, H. M., . . . Liao, C. T. (2025). Prognostic significance of diagnosis-to-surgery interval in oral cavity squamous cell carcinoma: A nationwide study. Oral Oncol, 161, 107196. https://doi.org/10.1016/j.oraloncology.2025.107196
  17. Kuo, Y. H., Ong, K. H., Sun, D. P., Tian, Y. F., Chou, C. L., Chan, T. C., Hsing, C. H., Li, W. S., Li, C. F., & Shiue, Y. L. (2025). Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma. Virchows Arch. https://doi.org/10.1007/s00428-025-04081-x
  18. Lee, W. C., Lin, Y. W., Shih, J. Y., Chen, Z. C., Wu, N. C., Chang, W. T., & Liu, P. Y. (2025). Dapagliflozin and Sirtuin-1 interaction and mechanism for ameliorating atrial fibrillation in a streptozotocin-induced rodent diabetic model. Biomol Biomed, 25(3), 608-622. https://doi.org/10.17305/bb.2024.11361
  19. Lin, H. Y., Chen, I. Y., Wang, T. M., Yen, C. H., Chen, Y., Chen, Y. H., Dai, D. F., Huang, J. F., Chiu, Y. W., & Yang, M. Y. (2025). The Role of Mitochondrial AKT1 Signaling in Renal Tubular Injury of Metabolic Syndrome. Kidney Int Rep, 10(3), 906-920. https://doi.org/10.1016/j.ekir.2024.12.021
  20. Lu, M. Y., Wei, Y. J., Wang, C. W., Liang, P. C., Yeh, M. L., Tsai, Y. S., Tsai, P. C., Ko, Y. M., Lin, C. C., Chen, K. Y., Lin, Y. H., Jang, T. Y., Hsieh, M. Y., Lin, Z. Y., Huang, C. F., Huang, J. F., Dai, C. Y., Chuang, W. L., & Yu, M. L. (2025). Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes. World J Gastroenterol, 31(10), 103716. https://doi.org/10.3748/wjg.v31.i10.103716
  21. Tsai, M. H., Yang, C. H., Tsai, Y. T., Lin, Y. T., Chao, C. Y., Chuang, H. C., Huang, T. L., Lu, H., Tsai, W. L., Chien, C. Y., & Fang, F. M. (2025). Controlling nutritional status score as a survival prognosticator in patients with head and neck cancer. J Formos Med Assoc. https://doi.org/10.1016/j.jfma.2025.04.017
  22. Tsai, Y. T., Wen, Y. W., Tsai, T. Y., Lin, C. Y., Ng, S. H., Ku, H. Y., Lou, P. J., Wang, C. P., Lin, J. C., Hua, C. H., Lee, S. R., Fan, K. H., Chen, W. C., Lee, L. Y., Chien, C. Y., Chen, T. M., Terng, S. D., Tsai, C. Y., Wang, H. M., . . . Liao, C. T. (2025). Pathological primary tumor status, rather than adjuvant therapy, predicts survival outcomes in pT1-3N1M0 oral cavity squamous cell carcinoma: A nationwide cohort study. Oral Oncol, 164, 107289. https://doi.org/10.1016/j.oraloncology.2025.107289
  23. Tseng, T. C., Hosaka, T., Pan, M. H., Liu, C. J., Suzuki, F., Chen, C. J., Su, T. H., Kumada, H., Yang, W. T., Yang, H. C., Liu, C. H., Chen, P. J., Yang, H. I., & Kao, J. H. (2025). Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients. Hepatology. https://doi.org/10.1097/hep.0000000000001313
  24. Wang, S. J., Huang, C. F., Chang, T. S., Lo, C. C., Hung, C. H., Huang, C. W., Chong, L. W., Cheng, P. N., Yeh, M. L., Peng, C. Y., Cheng, C. Y., Huang, J. F., Bair, M. J., Lin, C. L., Yang, C. C., Kuo, H. T., Hsieh, T. Y., Lee, T. H., Lee, P. L., . . . Yu, M. L. (2025). Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan. Kaohsiung J Med Sci, 41(2), e12929. https://doi.org/10.1002/kjm2.12929
  25. Wong, L. S., Yang, J. L., Yen, Y. T., Lee, C. H., & Yang, J. H. (2025). Endothelin-1 Participates in the Pathogenesis of Prurigo Nodularis by Promoting NGF Expression via Endothelial Receptor B in Epidermal Keratinocytes and Dorsal Root Ganglion Cells. Allergy. https://doi.org/10.1111/all.16564
  26. Wu, P. Y., Tsai, Y. T., Lin, Y. T., Chuang, H. C., Yang, C. H., Chien, C. Y., Fang, F. M., Huang, T. L., Lu, H., & Tsai, M. H. (2025). Assessment of Preoperative Systemic Inflammation Response Index in Surgically Treated Young Head and Neck Cancer Patients Under 40. Ear Nose Throat J, 1455613251338940. https://doi.org/10.1177/01455613251338940
  27. Yang, C. Y., Chen, J. H., Chen, C. Y., Kao, C. Y., Huang, S. F., Chang, W. Y., Tu, H. P., Huang, J. F., Yu, M. L., & Tai, C. M. (2025). Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study. Surg Obes Relat Dis, 21(5), 537-546. https://doi.org/10.1016/j.soard.2024.11.007
  28. Yen, L. J., Yen, C. Y., Li, C. L., Liao, E. C., Wang, K. C., Shih, M. C., Huang, H. S., Chen, Y. C., Lu, L. Y., & Yu, S. J. (2025). RETRACTED: Yen et al. Brevilin A Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis and Reduces Th17 Differentiation in Psoriasis Patients. J. Pers. Med. 2022, 12, 1888. J Pers Med, 15(2). https://doi.org/10.3390/jpm15020072
  29. Zhang, T., Huang, C. J., Chen, H. T., Huang, Y. H., Pan, M. H., Lee, M. H., Viard, M., Hildesheim, A., Pfeiffer, R. M., Carrington, M., Chen, C. J., Zhu, B., Lenz, T. L., Jiang, D., Yang, H. I., & Liu, Z. (2025). HLA-DQB1*03:01 and risk of HBV-related HCC. Hepatology. https://doi.org/10.1097/hep.0000000000001307

2024

  1. Chang, C. W., Hsu, W. F., Tseng, K. C., Chen, C. Y., Cheng, P. N., Hung, C. H., Lo, C. C., Bair, M. J., Chen, C. H., Lee, P. L., Lin, C. Y., Kuo, H. T., Chen, C. T., Yang, C. C., Huang, J. F., Tai, C. M., Hu, J. T., Lin, C. L., Su, W. W., . . . Peng, C. Y. (2024). Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan. Dig Dis Sci, 69(9), 3501-3512. https://doi.org/10.1007/s10620-024-08512-8
  2. Chang, W. T., Huang, P. S., Su, L. W., Liao, C. T., Siong Toh, H., Chen, Y. C., Ho, C. H., Chen, Z. C., Hsu, P. C., & Hong, C. S. (2024). Utility of the ACD-GENE-CLI Score in Asian Patients with Critical Limb Ischemia Undergoing Endovascular Interventions. J Atheroscler Thromb, 31(5), 572-586. https://doi.org/10.5551/jat.64326
  3. Chang, W. T., Lin, C. H., Lee, W. C., Kan, W. C., Lin, Y. C., Hiremath, P., Cheng, S., Liao, R., Chen, Z. C., Huang, P. S., & Wu, N. C. (2024). Signal intensity coefficient as a detector of aortic stenosis-induced myocardial fibrosis and its correlation to the long term outcome. Int J Cardiol, 394, 131367. https://doi.org/10.1016/j.ijcard.2023.131367
  4. Chang, W. T., Lin, Y. W., Chen, C. Y., Hong, C. S., Chen, Z. C., Lin, Y. C., & Shih, J. Y. (2024). The Combination of Valsartan and Spironolactone Mitigated Mitral Regurgitation-Induced Cardiac Dysfunction in a Novel Rat Model. J Cardiovasc Pharmacol, 84(4), 410-417. https://doi.org/10.1097/fjc.0000000000001614
  5. Chao, T. H., Lin, T. H., Cheng, C. I., Wu, Y. W., Ueng, K. C., Wu, Y. J., Lin, W. W., Leu, H. B., Cheng, H. M., Huang, C. C., Wu, C. C., Lin, C. F., Chang, W. T., Pan, W. H., Chen, P. R., Ting, K. H., Su, C. H., Chu, C. S., Chien, K. L., . . . Chen, W. J. (2024a). 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I. Acta Cardiol Sin, 40(5), 479-543. https://doi.org/10.6515/acs.202409_40(5).20240724a
  6. Chao, T. H., Lin, T. H., Cheng, C. I., Wu, Y. W., Ueng, K. C., Wu, Y. J., Lin, W. W., Leu, H. B., Cheng, H. M., Huang, C. C., Wu, C. C., Lin, C. F., Chang, W. T., Pan, W. H., Chen, P. R., Ting, K. H., Su, C. H., Chu, C. S., Chien, K. L., . . . Chen, W. J. (2024b). 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part II. Acta Cardiol Sin, 40(6), 669-715. https://doi.org/10.6515/acs.202411_40(6).20240724b
  7. Chen, C. Y., Chang, W. T., Lin, H. W., Lin, S. H., & Li, Y. H. (2024). Statin Use Is Associated With Reduced Heart Failure and Risk of Death in Non-Hodgkin Lymphoma. JACC CardioOncol, 6(1), 133-135. https://doi.org/10.1016/j.jaccao.2023.12.005
  8. Chen, Y. T., Chen, T. I., Yang, T. H., Yin, S. C., Lu, S. N., Liu, X. R., Gao, Y. Z., Lin, C. J., Huang, C. W., Huang, J. F., Yeh, M. L., Huang, C. F., Dai, C. Y., Chuang, W. L., Yang, H. I., Yu, M. L., & Lee, M. H. (2024). Long-term Risks of Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes. Am J Gastroenterol, 119(11), 2241-2250. https://doi.org/10.14309/ajg.0000000000002778
  9. Chen, Y. T., Chen, T. I., Yin, S. C., Huang, C. W., Huang, J. F., Lu, S. N., Yeh, M. L., Huang, C. F., Dai, C. Y., Chen, Y. W., Chuang, W. L., Yu, M. L., & Lee, M. H. (2024). Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease. J Gastroenterol Hepatol, 39(9), 1939-1949. https://doi.org/10.1111/jgh.16592
  10. Cheng, P. N., Chen, W. J., Hou, C. J., Lin, C. L., Chang, M. L., Wang, C. C., Chang, W. T., Wang, C. Y., Lin, C. Y., Hung, C. L., Peng, C. Y., Yu, M. L., Chao, T. H., Huang, J. F., Huang, Y. H., Chen, C. Y., Chiang, C. E., Lin, H. C., Li, Y. H., . . . Liu, C. J. (2024). Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases. Clin Mol Hepatol, 30(1), 16-36. https://doi.org/10.3350/cmh.2023.0315
  11. Cheng, P. N., Feng, I. C., Chen, J. J., Kuo, H. T., Lee, P. L., Yu, M. L., Chiu, Y. C., Chiu, H. C., Chien, S. C., Chen, P. J., & Liu, C. J. (2024). Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Aliment Pharmacol Ther, 59(2), 230-238. https://doi.org/10.1111/apt.17765
  12. Cheng, P. N., & Yu, M. L. (2024a). Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer. Clin Mol Hepatol, 30(2), 144-146. https://doi.org/10.3350/cmh.2024.0115
  13. Cheng, P. N., & Yu, M. L. (2024b). Reply to correspondence on "Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide". Clin Mol Hepatol, 30(4), 1031-1032. https://doi.org/10.3350/cmh.2024.0228
  14. Chong, J. H., Chang, W. T., Chan, J. J., Tan, T. J. Y., Chan, J. W. K., Wong, M., Wong, F. Y., & Chuah, C. T. H. (2024). The cardioprotective potential of sodium-glucose cotransporter 2-inhibitors in breast cancer therapy-related cardiac dysfunction - A systematic review. Curr Probl Cardiol, 49(3), 102372. https://doi.org/10.1016/j.cpcardiol.2024.102372
  15. Hong, R. L., Yen, C. J., Lien, M. Y., Cheng, R., Su, Y. W., Lin, H. N., Poon, S. L., & Chien, C. Y. (2024). Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study. Oral Oncol, 152, 106760. https://doi.org/10.1016/j.oraloncology.2024.106760
  16. Huang, C. C., Hsu, C. M., Chao, M. W., Hsu, K. C., Lin, T. E., Yen, S. C., Tu, H. J., & Pan, S. L. (2024). In silico identification of a novel Cdc2-like kinase 2 (CLK2) inhibitor in triple negative breast cancer. Protein Sci, 33(6), e5004. https://doi.org/10.1002/pro.5004
  17. Huang, C. F., Awad, M. H., Gal-Tanamy, M., & Yu, M. L. (2024a). Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication". Clin Mol Hepatol, 30(4), 1023-1025. https://doi.org/10.3350/cmh.2024.0472
  18. Huang, C. F., Awad, M. H., Gal-Tanamy, M., & Yu, M. L. (2024b). Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication. Clin Mol Hepatol, 30(3), 326-344. https://doi.org/10.3350/cmh.2024.0155
  19. Huang, C. F., Dai, C. Y., Lin, Y. H., Wang, C. W., Jang, T. Y., Liang, P. C., Lin, T. C., Tsai, P. C., Wei, Y. J., Yeh, M. L., Hsieh, M. Y., Huang, C. K., Huang, J. F., Chuang, W. L., & Yu, M. L. (2024). Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan. Clin Mol Hepatol, 30(4), 883-894. https://doi.org/10.3350/cmh.2024.0414
  20. Huang, C. F., Kroeniger, K., Wang, C. W., Jang, T. Y., Yeh, M. L., Liang, P. C., Wei, Y. J., Hsu, P. Y., Huang, C. I., Hsieh, M. Y., Lin, Y. H., Huang, J. F., Dai, C. Y., Chuang, W. L., Sharma, A., & Yu, M. L. (2024). Surveillance Imaging and GAAD/GALAD Scores for Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis. J Clin Transl Hepatol, 12(11), 907-916. https://doi.org/10.14218/jcth.2024.00172
  21. Huang, C. F., Liang, P. C., Tsai, P. C., Wei, Y. J., Huang, C. I., Wang, C. W., Jang, T. Y., Yeh, M. L., Hsu, P. Y., Hsieh, M. Y., Lin, Y. H., Dai, C. Y., Chuang, W. L., Huang, J. F., & Yu, M. L. (2024). The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area. J Gastroenterol Hepatol, 39(1), 193-201. https://doi.org/10.1111/jgh.16363
  22. Huang, C. F., Liang, P. C., Wang, C. W., Jang, T. Y., Hsu, P. Y., Tsai, P. C., Wei, Y. J., Yeh, M. L., Hsieh, M. Y., Lin, Y. H., Huang, C. K., Dai, C. Y., Huang, J. F., Chuang, W. L., & Yu, M. L. (2024). Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis. Kaohsiung J Med Sci, 40(4), 374-383. https://doi.org/10.1002/kjm2.12804
  23. Huang, C. F., Yeh, M. L., Dai, C. Y., Huang, J. F., Chuang, W. L., & Yu, M. L. (2024). Chronic Hepatitis C Related Steatotic Liver Disease Is More Than "Miscellaneous Steatotic Liver Disease". Clin Gastroenterol Hepatol, 22(10), 2137-2139.e2132. https://doi.org/10.1016/j.cgh.2024.04.023
  24. Huang, D. Q., Hoang, J. K., Kamal, R., Tsai, P. C., Toyoda, H., Yeh, M. L., Yasuda, S., Leong, J., Maeda, M., Huang, C. F., Won Jun, D., Ishigami, M., Tanaka, Y., Uojima, H., Ogawa, E., Abe, H., Hsu, Y. C., Tseng, C. H., Alsudaney, M., . . . Nguyen, M. H. (2024). Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma. J Clin Oncol, 42(7), 790-799. https://doi.org/10.1200/jco.23.00757
  25. Huang, J. F., Chang, T. J., Yeh, M. L., Shen, F. C., Tai, C. M., Chen, J. F., Huang, Y. H., Hsu, C. Y., Cheng, P. N., Lin, C. L., Hung, C. H., Chen, C. C., Lee, M. H., Lee, C. C., Lin, C. W., Liu, S. C., Yang, H. I., Chien, R. N., Kuo, C. S., . . . Yu, M. L. (2024). Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus. Hepatol Commun, 8(11). https://doi.org/10.1097/hc9.0000000000000571
  26. Hung, C. L., Wu, Y. W., Kuo, L., Sung, K. T., Lin, H. H., Chang, W. T., Chang, C. H., Lai, C. H., Huang, C. Y., Wang, C. L., Lin, C. C., Juang, J. J., Chen, P. S., Wang, C. Y., Chang, H. C., Chu, C. Y., Wang, W. H., Tseng, H., Kao, Y. T., . . . Chen, W. J. (2024). 2024 Update of the TSOC Expert Consensus of Fabry Disease. Acta Cardiol Sin, 40(5), 544-568. https://doi.org/10.6515/acs.202409_40(5).20240731a
  27. Jang, T. Y., Ho, C. C., Liang, P. C., Wu, C. D., Wei, Y. J., Tsai, P. C., Hsu, P. Y., Hsieh, M. Y., Lin, Y. H., Hsieh, M. H., Wang, C. W., Yang, J. F., Yeh, M. L., Huang, C. F., Chuang, W. L., Huang, J. F., Cheng, Y. Y., Dai, C. Y., Chen, P. C., & Yu, M. L. (2024). Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease. Kaohsiung J Med Sci, 40(3), 304-314. https://doi.org/10.1002/kjm2.12781
  28. Jang, T. Y., Huang, C. F., Chang, T. S., Yang, C. C., Lo, C. C., Hung, C. H., Huang, C. W., Chong, L. W., Cheng, P. N., Yeh, M. L., Peng, C. Y., Cheng, C. Y., Huang, J. F., Bair, M. J., Lin, C. L., Yang, C. C., Wang, S. J., Hsieh, T. Y., Lee, T. H., . . . Yu, M. L. (2024). Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry. J Formos Med Assoc. https://doi.org/10.1016/j.jfma.2024.08.013
  29. Jang, T. Y., Liang, P. C., Jun, D. W., Jung, J. H., Toyoda, H., Wang, C. W., Yuen, M. F., Cheung, K. S., Yasuda, S., Kim, S. E., Yoon, E. L., An, J., Enomoto, M., Kozuka, R., Chuma, M., Nozaki, A., Ishikawa, T., Watanabe, T., Atsukawa, M., . . . Yu, M. L. (2024). Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study. J Gastroenterol Hepatol, 39(6), 1190-1197. https://doi.org/10.1111/jgh.16537
  30. Ji, F., Tran, S., Ogawa, E., Huang, C. F., Suzuki, T., Wong, Y. J., Toyoda, H., Jun, D. W., Li, L., Uojima, H., Nozaki, A., Chuma, M., Tseng, C. H., Hsu, Y. C., Ishigami, M., Honda, T., Atsukawa, M., Haga, H., Enomoto, M., . . . Nguyen, M. H. (2024). Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study. J Clin Transl Hepatol, 12(7), 646-658. https://doi.org/10.14218/jcth.2024.00089
  31. Kelberman, M. A., Rodberg, E., Arabzadeh, E., Bair-Marshall, C. J., Berridge, C. W., Berrocoso, E., Breton-Provencher, V., Chandler, D. J., Che, A., Davy, O., Devilbiss, D. M., Downs, A. M., Drummond, G., Dvorkin, R., Fazlali, Z., Froemke, R. C., Glennon, E., Gold, J. I., Ito, H., . . . Totah, N. K. (2024). Diversity of ancestral brainstem noradrenergic neurons across species and multiple biological factors. bioRxiv. https://doi.org/10.1101/2024.10.14.618224
  32. Kudaravalli, S., Huang, D. Q., Yeh, M. L., Trinh, L., Tsai, P. C., Hsu, Y. C., Kam, L. Y., Nguyen, V. H., Ogawa, E., Lee, D. H., Ito, T., Watanabe, T., Enomoto, M., Preda, C. M., Ko, M. K. L., Wan-Hin Hui, R., Atsukawa, M., Suzuki, T., Marciano, S., . . . Nguyen, M. H. (2024). Sex and ethnic disparities in hepatitis B evaluation and treatment across the world. J Hepatol, 81(1), 33-41. https://doi.org/10.1016/j.jhep.2024.02.033
  33. Lee, M. H., Chen, Y. T., Huang, Y. H., Lu, S. N., Yang, T. H., Huang, J. F., Yin, S. C., Yeh, M. L., Huang, C. F., Dai, C. Y., Chuang, W. L., Yu, M. L., Yang, H. I., Chen, H. Y., & Chen, C. J. (2024). Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC. Clin Gastroenterol Hepatol, 22(6), 1275-1285.e1272. https://doi.org/10.1016/j.cgh.2024.01.045
  34. Lee, W. C., Lin, Y. W., Shih, J. Y., Chen, Z. C., Wu, N. C., & Chang, W. T. (2024). Ivabradine could not decrease mitral regurgitation triggered atrial fibrosis and fibrillation compared with carvedilol. ESC Heart Fail, 11(1), 251-260. https://doi.org/10.1002/ehf2.14577
  35. Lin, H. C., Jeng, W. J., Liu, J., Pan, M. H., Lee, M. H., Batrla-Utermann, R., Lu, S. N., Chen, C. F., Yang, H. I., & Chen, C. J. (2024). Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther, 59(8), 993-1002. https://doi.org/10.1111/apt.17915
  36. Lin, H. Y., Liang, C. J., Yang, M. Y., Chen, P. L., Wang, T. M., Chen, Y. H., Shih, Y. H., Liu, W., Chiu, C. C., Chiang, C. K., Lin, C. S., & Lin, H. C. (2024). Critical roles of tubular mitochondrial ATP synthase dysfunction in maleic acid-induced acute kidney injury. Apoptosis, 29(5-6), 620-634. https://doi.org/10.1007/s10495-023-01897-3
  37. Lin, Y. C., Shih, J. Y., Lin, Y. W., Niu, K. C., Hong, C. S., Chen, Z. C., Pan, S. C., Chang, T. Y., Kan, W. C., & Chang, W. T. (2024). Hyperbaric Oxygen Therapy Improved Neovascularisation Following Limb Ischaemia-The Role of ROS Mitigation. J Cell Mol Med, 28(24), e70310. https://doi.org/10.1111/jcmm.70310
  38. Liu, C. J., Seto, W. K., & Yu, M. L. (2024). Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD. Hepatol Int, 18(Suppl 2), 897-908. https://doi.org/10.1007/s12072-024-10699-x
  39. Lonardo, A., Bril, F., Caldwell, S. H., Eslam, M., Fan, J. G., Gish, R. G., Gronbaek, H., Sanal, M. G., Stefan, N., Suzuki, A., Targher, G., Tilg, H., Yu, M. L., Zheng, M. H., & George, J. (2024). Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature. J Hepatol, 80(5), e192-e194. https://doi.org/10.1016/j.jhep.2024.01.012
  40. Lu, M. Y., Chuang, W. L., & Yu, M. L. (2024). The role of artificial intelligence in the management of liver diseases. Kaohsiung J Med Sci, 40(11), 962-971. https://doi.org/10.1002/kjm2.12901
  41. Lu, M. Y., Huang, C. F., Hung, C. H., Tai, C. M., Mo, L. R., Kuo, H. T., Tseng, K. C., Lo, C. C., Bair, M. J., Wang, S. J., Huang, J. F., Yeh, M. L., Chen, C. T., Tsai, M. C., Huang, C. W., Lee, P. L., Yang, T. H., Huang, Y. H., Chong, L. W., . . . Yu, M. L. (2024). Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program. Clin Mol Hepatol, 30(1), 64-79. https://doi.org/10.3350/cmh.2023.0287
  42. Lu, M. Y., & Yu, M. L. (2024). Correspondence on Letter regarding "Toward hepatitis C virus elimination using artificial intelligence". Clin Mol Hepatol, 30(2), 274-275. https://doi.org/10.3350/cmh.2024.0152
  43. Mukherji, A., Jühling, F., Simanjuntak, Y., Crouchet, E., Del Zompo, F., Teraoka, Y., Haller, A., Baltzinger, P., Paritala, S., Rasha, F., Fujiwara, N., Gadenne, C., Slovic, N., Oudot, M. A., Durand, S. C., Ponsolles, C., Schuster, C., Zhuang, X., Holmes, J., . . . Baumert, T. F. (2024). An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection. Nat Commun, 15(1), 7486. https://doi.org/10.1038/s41467-024-51698-8
  44. Pan, Z., Khatry, M. A., Yu, M. L., Choudhury, A., Sebastiani, G., Alqahtani, S. A., & Eslam, M. (2024). MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight. Ther Adv Endocrinol Metab, 15, 20420188241252543. https://doi.org/10.1177/20420188241252543
  45. Park, J. E., Nguyen, V. H., Tsai, P. C., Toyoda, H., Leong, J., Guy, J. E., Yeh, M. L., Huang, C. F., Yasuda, S., Abe, H., Hsu, Y. C., Tseng, C. H., Liu, J., Chen, Y. L., Lin, P. Y., Jun, D. W., Yoshimaru, Y., Ogawa, E., Ishigami, M., . . . Nguyen, M. H. (2024). Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response. Aliment Pharmacol Ther, 59(6), 742-751. https://doi.org/10.1111/apt.17863
  46. Shen, H. C., Pan, M. H., Huang, C. J., Yeh, H. Y., Yang, H. I., Lin, Y. H., Huang, C. C., Lee, K. C., Yang, Y. Y., & Hou, M. C. (2024). Multiple genetic polymorphisms are associated with the risk of metabolic syndrome, fatty liver, and airflow limitation: A Taiwan Biobank study. Gene, 927, 148660. https://doi.org/10.1016/j.gene.2024.148660
  47. Shih, C. I., Wu, K. T., Hsieh, M. H., Yang, J. F., Chen, Y. Y., Tsai, W. L., Chen, W. C., Liang, P. C., Wei, Y. J., Tsai, P. C., Hsu, P. Y., Hsieh, M. Y., Lin, Y. H., Jang, T. Y., Wang, C. W., Yeh, M. L., Huang, C. F., Huang, J. F., Dai, C. Y., . . . Yu, M. L. (2024). Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study. Hepatol Int, 18(1), 138-154. https://doi.org/10.1007/s12072-023-10576-z
  48. Tai, C. M., & Yu, M. L. (2024). Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide. Kaohsiung J Med Sci, 40(2), 112-118. https://doi.org/10.1002/kjm2.12788
  49. Tsai, P. C., Huang, C. F., Yeh, M. L., Hsieh, M. H., Kuo, H. T., Hung, C. H., Tseng, K. C., Lai, H. C., Peng, C. Y., Wang, J. H., Chen, J. J., Lee, P. L., Chien, R. N., Yang, C. C., Lo, G. H., Kao, J. H., Liu, C. J., Liu, C. H., Yan, S. L., . . . Yu, M. L. (2024). Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy. Clin Mol Hepatol, 30(3), 468-486. https://doi.org/10.3350/cmh.2024.0038
  50. Tsai, Y. T., Chen, W. C., Wen, Y. W., Lin, C. Y., Fan, K. H., Lin, J. C., Ng, S. H., Lee, S. R., Kang, C. J., Lee, L. Y., Chien, C. Y., Hua, C. H., Wang, C. P., Chen, T. M., Terng, S. D., Tsai, C. Y., Wang, H. M., Hsieh, C. H., Yeh, C. H., . . . Liao, C. T. (2024). Prognostic significance of adjuvant therapy and specific radiation dosages in Taiwanese patients with oral cavity cancer and extra-nodal extension: a nationwide cohort study. BMC Cancer, 24(1), 1320. https://doi.org/10.1186/s12885-024-13048-1
  51. Tu, H. J., Chao, M. W., Lee, C. C., Peng, C. S., Wu, Y. W., Lin, T. E., Chang, Y. W., Yen, S. C., Hsu, K. C., Pan, S. L., & HuangFu, W. C. (2024). Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation. J Enzyme Inhib Med Chem, 39(1), 2418470. https://doi.org/10.1080/14756366.2024.2418470
  52. Wang, C. W., Huang, C. F., Yeh, M. L., Chen, S. C., Hung, C. H., Kuo, C. H., Huang, J. F., Dai, C. Y., Chuang, W. L., & Lung-Yu, M. (2024). Hepatitis C virus infection associated with coronary and thoracic aortic atherosclerosis. Am J Med Sci, 368(3), 203-213. https://doi.org/10.1016/j.amjms.2024.02.004
  53. Wang, C. W., Huang, C. F., Yeh, M. L., Liang, P. C., Jang, T. Y., Wei, Y. J., Hsu, P. Y., Hsieh, M. Y., Lin, Y. H., Huang, J. F., Dai, C. Y., Chuang, W. L., & Yu, M. L. (2024). Assessment of hepatitis B virus relapse in cancer patients receiving chemotherapy with prophylactic nucleos(t)ide analogues: Implications for overall mortality. Liver Int, 44(10), 2592-2604. https://doi.org/10.1111/liv.16030
  54. Wang, K. C., Sun, Y. S., Tsai, H. C., Liao, H. T., Lai, C. C., Chen, W. S., Lu, L. Y., & Chen, M. H. (2024). Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study. Mod Rheumatol, 34(5), 1027-1035. https://doi.org/10.1093/mr/roae004
  55. Yang, C. C., Huang, C. F., Chang, T. S., Lo, C. C., Hung, C. H., Huang, C. W., Chong, L. W., Cheng, P. N., Yeh, M. L., Peng, C. Y., Cheng, C. Y., Huang, J. F., Bair, M. J., Lin, C. L., Yang, C. C., Wang, S. J., Hsieh, T. Y., Lee, T. H., Lee, P. L., . . . Yu, M. L. (2024). Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan. Infect Dis Ther, 13(6), 1199-1213. https://doi.org/10.1007/s40121-024-00968-5
  56. Yen, L. J., Chen, Y. C., Wang, K. C., Shih, M. C., Li, C. L., Yu, S. J., & Lu, L. Y. (2024). Hydroxychloroquine exacerbates imiquimod-induced psoriasis-like dermatitis through stimulating overexpression of IL-6 in keratinocytes. Immunopharmacol Immunotoxicol, 46(1), 128-137. https://doi.org/10.1080/08923973.2023.2281283
  57. Younossi, Z. M., Alqahtani, S. A., Alswat, K., Yilmaz, Y., Keklikkiran, C., Funuyet-Salas, J., Romero-Gómez, M., Fan, J. G., Zheng, M. H., El-Kassas, M., Castera, L., Liu, C. J., Wai-Sun Wong, V., Zelber-Sagi, S., Allen, A. M., Lam, B., Treeprasertsuk, S., Hameed, S., Takahashi, H., . . . Lazarus, J. V. (2024). Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol, 80(3), 419-430. https://doi.org/10.1016/j.jhep.2023.11.004
  58. Younossi, Z. M., AlQahtani, S. A., Funuyet-Salas, J., Romero-Gómez, M., Yilmaz, Y., Keklikkiran, C., Alswat, K., Yu, M. L., Liu, C. J., Fan, J. G., Zheng, M. H., Burra, P., Francque, S. M., Castera, L., Schattenberg, J. M., Newsome, P. N., Allen, A. M., El-Kassas, M., Treeprasertsuk, S., . . . Lazarus, J. V. (2024). The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep, 6(7), 101066. https://doi.org/10.1016/j.jhepr.2024.101066
  59. Zeng, X. F., Varady, K. A., Wang, X. D., Targher, G., Byrne, C. D., Tayyem, R., Latella, G., Bergheim, I., Valenzuela, R., George, J., Newberry, C., Zheng, J. S., George, E. S., Spearman, C. W., Kontogianni, M. D., Ristic-Medic, D., Peres, W. A. F., Depboylu, G. Y., Yang, W., . . . Zheng, M. H. (2024). The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. Metabolism, 161, 156028. https://doi.org/10.1016/j.metabol.2024.156028
  60. Zhang, H., Targher, G., Byrne, C. D., Kim, S. U., Wong, V. W., Valenti, L., Glickman, M., Ponce, J., Mantzoros, C. S., Crespo, J., Gronbaek, H., Yang, W., Eslam, M., Wong, R. J., Machado, M. V., Yu, M. L., Ghanem, O. M., Okanoue, T., Liu, J. F., . . . Zheng, M. H. (2024). A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatol Int, 18(4), 1178-1201. https://doi.org/10.1007/s12072-024-10702-5

2023

  1. Chang, W. T., Lee, W. C., Lin, Y. W., Shih, J. Y., Hong, C. S., Chen, Z. C., Chu, C. Y., & Hsu, C. H. (2023). Transpulmonary Expression of Exosomal microRNAs in Idiopathic and Congenital Heart Disease-Related Pulmonary Arterial Hypertension. J Am Heart Assoc, 12(23), e031435. https://doi.org/10.1161/jaha.123.031435
  2. Chang, W. T., Liu, C. C., Huang, Y. T., Wu, J. Y., Tsai, W. W., Hung, K. C., Chen, I. W., & Feng, P. H. (2023). Diagnostic efficacy of the triglyceride-glucose index in the prediction of contrast-induced nephropathy following percutaneous coronary intervention. Front Endocrinol (Lausanne), 14, 1282675. https://doi.org/10.3389/fendo.2023.1282675
  3. Chang, W. T., Sun, C. K., Wu, J. Y., Yu, C. H., Chang, Y. J., Lin, M. C., Lan, K. M., Chen, I. W., & Hung, K. C. (2023). Association of prognostic nutritional index with long-term mortality in patients receiving percutaneous coronary intervention for acute coronary syndrome: a meta-analysis. Sci Rep, 13(1), 13102. https://doi.org/10.1038/s41598-023-40312-4
  4. Chang, W. T., Wu, C. C., Liao, I. C., Lin, Y. W., Chen, Y. C., Ho, C. H., Lee, W. C., Lin, Y. C., Chen, Z. C., Shih, J. Y., Wu, N. C., & Kan, W. C. (2023). Dapagliflozin protects against doxorubicin-induced nephrotoxicity associated with nitric oxide pathway-A translational study. Free Radic Biol Med, 208, 103-111. https://doi.org/10.1016/j.freeradbiomed.2023.08.013
  5. Chen, C. Y., Chen, T. T., Feng, Y. A., Yu, M., Lin, S. C., Longchamps, R. J., Wang, S. H., Hsu, Y. H., Yang, H. I., Kuo, P. H., Daly, M. J., Chen, W. J., Huang, H., Ge, T., & Lin, Y. F. (2023). Analysis across Taiwan Biobank, Biobank Japan, and UK Biobank identifies hundreds of novel loci for 36 quantitative traits. Cell Genom, 3(12), 100436. https://doi.org/10.1016/j.xgen.2023.100436
  6. Huang, C. F., Jang, T. Y., Wu, P. H., Kuo, M. C., Yeh, M. L., Wang, C. W., Liang, P. C., Wei, Y. J., Hsu, P. Y., Huang, C. I., Hsieh, M. Y., Lin, Y. H., Hsiao, H. H., Hsu, C. M., Huang, C. T., Lee, C. Y., Chen, Y. H., Chen, T. C., Lin, K. D., . . . Yu, M. L. (2023). Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort. Virol J, 20(1), 112. https://doi.org/10.1186/s12985-023-02056-5
  7. Huang, C. T., Lee, C. P., Chen, T. Y., Liu, Y. C., Cho, S. F., Du, J. S., Yu, M. L., Huang, C. F., Wang, S. F., & Hsiao, H. H. (2023). Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies. J Clin Med, 12(17). https://doi.org/10.3390/jcm12175647
  8. Huang, J. F., Tsai, P. C., Yeh, M. L., Huang, C. F., Huang, C. I., Lee, M. H., Hsu, P. Y., Wang, C. W., Wei, Y. J., Liang, P. C., Lin, Y. H., Hsieh, M. H., Yang, J. F., Hsieh, M. Y., Jang, T. Y., Bair, M. J., Lin, Z. Y., Dai, C. Y., Yu, M. L., & Chuang, W. L. (2023). Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease. J Clin Transl Hepatol, 11(5), 1061-1068. https://doi.org/10.14218/jcth.2022.00103s
  9. Lee, S., Chao, M. W., Wu, Y. W., Hsu, C. M., Lin, T. E., Hsu, K. C., Pan, S. L., & Lee, H. Y. (2023). Synthesis and evaluation of potent (iso)ellipticine-based inhibitors of MYLK4 accessed via expeditious synthesis from isoquinolin-5-ol. RSC Adv, 13(45), 31595-31601. https://doi.org/10.1039/d3ra06600b
  10. Lin, Z. Y., Yeh, M. L., Liang, P. C., Hsu, P. Y., Huang, C. F., Huang, J. F., Dai, C. Y., Yu, M. L., & Chuang, W. L. (2023). Dose Consideration of Lenvatinib's Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy. Cancers (Basel), 15(20). https://doi.org/10.3390/cancers15205097
  11. Lu, C. Y., Kao, C. L., Hung, K. C., Wu, J. Y., Hsu, H. C., Yu, C. H., Chang, W. T., Feng, P. H., & Chen, I. W. (2023). Diagnostic efficacy of serum presepsin for postoperative infectious complications: a meta-analysis. Front Immunol, 14, 1320683. https://doi.org/10.3389/fimmu.2023.1320683
  12. Peng, B. R., Zheng, L. G., Chen, L. Y., El-Shazly, M., Hwang, T. L., Su, J. H., Lee, M. H., Lai, K. H., & Sung, P. J. (2023). Nor-24-homoscalaranes, Neutrophilic Inflammatory Mediators from the Marine Sponge Lendenfeldia sp. Pharmaceuticals (Basel), 16(9). https://doi.org/10.3390/ph16091258
  13. Perez, S., Lavi-Itzkovitz, A., Gidoni, M., Domovitz, T., Dabour, R., Khurana, I., Davidovich, A., Tobar, A., Livoff, A., Solomonov, E., Maman, Y., El-Osta, A., Tsai, Y., Yu, M. L., Stemmer, S. M., Haviv, I., Yaari, G., & Gal-Tanamy, M. (2023). High-Resolution Genomic Profiling of Liver Cancer Links Etiology With Mutation and Epigenetic Signatures. Cell Mol Gastroenterol Hepatol, 16(1), 63-81. https://doi.org/10.1016/j.jcmgh.2023.03.004
  14. Shih, M. C., Li, C. L., Liao, E. C., Yen, C. Y., Yen, L. J., Wang, K. C., Lu, L. Y., Chou, T. Y., Chen, Y. C., & Yu, S. J. (2023). Inhibition of NLRP3 Inflammasome Activation by 3H-1,2-Dithiole-3-Thione: A Potential Therapeutic Approach for Psoriasis Treatment. Int J Mol Sci, 24(17). https://doi.org/10.3390/ijms241713528
  15. Tsai, Y. C., Yu, M. L., Ko, C. Y., Hsin, Y. H., Tsai, Q. Z., & Huang, C. W. (2023). Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis. BMJ Open, 13(6), e070490. https://doi.org/10.1136/bmjopen-2022-070490
  16. Yu, M. L., & Ward, J. W. (2023). Sharing Lessons Learned to Build Effective Hepatitis Elimination Programs. J Infect Dis, 228(Suppl 3), S145-s147. https://doi.org/10.1093/infdis/jiad342
瀏覽數: